Skip to main content
Bildspel: 

CORRECTION: NOTICE OF ANNUAL GENERAL MEETING IN MOBERG DERMA

This notice replaces the previous notice of Annual General Meeting in Moberg Derma AB (publ). The proposal on the Employee Stock Option Plan 2012:1, to be addressed under item 15 on the agenda for the Annual General Meeting, is corrected as to the number of employee stock options than can be allotted and the number of warrants that can be issued. Shareholders in Moberg Derma AB (publ) (reg. no. 556697-7426) (the ”Company”) are hereby convened to the Annual General Meeting on Monday, April 23, 2012 at 5.30 p.m. in the Company’s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.

The correction in brief

The proposal on the Employee Stock Option Plan 2012:1, to be addressed under item 15 on the agenda for the Annual General Meeting, is corrected as to the number of employee stock options that can be allotted and the number of warrants that can be issued. The number of employee stock options that can be allotted is increased from a maximum of 43,750 to a maximum of 50,750 employee stock options. The number of warrants that can be issued are increased from a maximum 57,496 to a maximum of 66,696 warrants. As a consequence, the number of warrants intended to hedge costs that may arise from the employee stock option plan are increased from a maximum of 13,746 to a maximum of 15,946 warrants. In the event that all warrants issued in respect of Employee Stock Option Plan 2012:1 are used to subscribe for new shares, the Company’s share capital will increase by SEK 6,669.60 from SEK 907,902 to SEK 914,571.60.

The proposal is otherwise unchanged.

The complete notice is attached.

About this information
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 04:00 pm (CET) on March 23th, 2012.

For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se